Shuttle Pharmaceuticals Holdings, Inc. — Form 8-K Summary
Report date: October 16, 2026 (filed October 22, 2026). This is a corporate-governance and auditor-change filing, not a report of quarterly financial results.
Business context and reporting period
The Audit Committee and Board approved dismissing Forvis Mazars, LLP as the Company’s independent registered public accounting firm, effective after filing the Form 10-Q for the quarter ended September 30, 2026. The Company had not engaged a successor auditor as of the 8-K filing.
Financial condition and key metrics
The filing provides no revenue, earnings, cash flow, margin, debt, or liquidity figures. Forvis Mazars’ audit reports for fiscal 2024 and 2025 were not adverse, disclaimed, or qualified, but each included an explanatory paragraph raising substantial doubt about the Company’s ability to continue as a going concern.
Material changes, controls, and unusual items
- The Company reported no disagreements with Forvis Mazars on accounting principles, financial-statement disclosure, or audit scope or procedures during fiscal 2024 and 2025 or the subsequent interim period through October 16, 2026.
- It reported no other reportable events, except previously disclosed material weaknesses in internal control over financial reporting.
- Identified control deficiencies include limited written accounting and financial-close procedures; inadequate review and segregation of duties for certain transactions, journal entries, and spreadsheets; IT general-control issues involving super-user access and segregation of duties; and weaknesses in communicating material contracts and other information for accounting purposes.
- The Company also disclosed insufficient in-house technical accounting and valuation expertise for complex or non-routine transactions. Controls over independently assessing third-party specialists’ conclusions and valuations were not adequately designed or operating effectively, creating a reasonable possibility that material misstatements would not be prevented or detected timely.
Outlook, risks, and contingencies
The filing gives no financial guidance or operating outlook. The going-concern explanatory paragraphs and the disclosed material weaknesses are important risks. The Company authorized Forvis Mazars to respond to the successor auditor’s inquiries about the weaknesses. Forvis Mazars’ letter dated October 21, 2026, is included as Exhibit 16.1.
Important facts for investors to verify
- Whether the Company appointed a successor auditor and whether the transition was completed after the September 30, 2026 Form 10-Q.
- Whether the successor auditor identified additional issues concerning the disclosed control weaknesses or prior accounting.
- Management’s remediation progress and the status of the going-concern risk in subsequent filings.
- The contents of Forvis Mazars’ Exhibit 16.1 letter.